Background: Up to 50% of patients with nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease (N‐ERD) exhibit a noneosinophilic airway inflammatory phenotype, with paucigranulocytic asthma being the most prevalent. The aim was to identify clusters within N‐ERD and aspirin‐tolerant asthma (ATA) controls with a paucigranulocytic asthma phenotype. Methods: Two separate hierarchical cluster analyses were performed using 23 variables in 36 N‐ERD patients and 19 ATA controls. Variables included demographic, clinical, treatment‐related, and hematologic parameters; sputum cytology; sinus computed tomography findings; and eicosanoid levels in induced sputum supernatant (ISS) and urine. Results: Two clusters were identified in each group: 1 N‐ERD , 2 N‐ERD , 1 ATA , and 2 ATA . Cluster 1 N‐ERD patients had less severe asthma and required lower doses of inhaled corticosteroids (ICS) but showed higher blood eosinophil counts, Lund‐Mackay (LM) scores, and ISS leukotriene E 4 (LTE 4 ) levels than those in cluster 2 N‐ERD . Cut‐off values defining a T2‐high paucigranulocytic asthma profile in N‐ERD included LM score ≥ 18, blood eosinophils ≥ 300 cells/mm 3 , and ISS LTE 4 ≥ 30 pg/mL, with the LM score demonstrating the highest AUC at 0.8. Among ATA controls, cluster 1 ATA had more severe asthma, higher ICS doses, more severe sinonasal disease, and increased ISS leukotriene D 4 and LTE 4 levels compared with cluster 2 ATA . Conclusion: Two clusters were identified among N‐ERD patients with a paucigranulocytic asthma phenotype. Cluster 1 N‐ERD was characterized by milder asthma, more severe sinonasal disease, elevated blood eosinophil counts, and elevated ISS LTE 4 . This T2‐high‐like cluster may represent a subgroup requiring further evaluation for anti‐T2 biologic therapy targeting chronic rhinosinusitis with nasal polyps, although further validation is required.